BLAINJECTIONINJECTABLE
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
AVZIVI (bevacizumab) by Bio-Thera Solutions is 12. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVZIVI (bevacizumab) is a monoclonal antibody that binds VEGF and blocks angiogenesis by preventing VEGF interaction with endothelial cell receptors (Flt-1 and KDR). This mechanism inhibits new blood vessel formation and microvascular growth, reducing metastatic disease progression in solid tumors. The drug is indicated for oncology use and approved as a biosimilar reference product by Bio-Thera Solutions.
Growth
Early-stage product in growth phase with 30% competitive pressure; commercial teams are scaling post-launch infrastructure and market access strategies.
Mechanism of Action
12.1 Mechanism of Action Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of…
Worked on AVZIVI at Bio-Thera Solutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.